Although, several reports have described advantages and disadvantages of common ROAs for CBD (oral, sublingual, topical, inhalant, intranasal, rectal, and parenteral) individually [37,38], to date, no conclusive studies have investigated the features and outcomes of ROAs in a comparative fashion specifically regarding epileptic seizures with CBD treatment. The gene discussed is OPN1MW; the disease is Seizure.